ClinicalTrials.gg
CompletedNCT00349375Updated Jul 8, 2009

Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy

A Phase 3 interventional study of Fenofibrate/Simvastatin and Fenofibrate/Simvastatin in Hyperlipidemia, sponsored by Solvay Pharmaceuticals. Completed at 110 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-07-08.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,040
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing fenofibrate in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Fenofibrate · Hyperlipidemias.

Enrollment
Largest of 14
1,040 · median 178
Started
2005
with 2 others
Phase 3
7 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
4 of 14
Solvay Pharmaceuticals

Among the 14 studies testing fenofibrate in Hyperlipidemias, this one has the largest enrollment, is one of 3 that started in 2005, is one of 7 in phase 3, and was the 6th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 14 studies testing fenofibrate in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing fenofibrate in Hyperlipidemias as a file.
02

Study summary

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mixed dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Known to fenofibrate or simvastatin
  • Pregnant or lactating women
  • to fenofibrate or simvastatin
  • Unstable or severe cardiac disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,040 participants (actual)

Study arms

  • Experimental
    1

    Drug: Fenofibrate/Simvastatin

  • Experimental
    2

    Drug: Fenofibrate/Simvastatin

  • Active comparator
    3

    Drug: Simvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 24 weeks of treatment in Triglycerides

    Time frame: 12 weeks

  2. Percent change from baseline to 24 weeks of treatment in HDL-C

    Time frame: 12 weeks

  3. Percent change from baseline to 24 weeks of treatment in LDL-C

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change from baseline to 24 weeks of treatment in Triglycerides

    Time frame: 24 weeks

  2. Percent change from baseline to 24 weeks of treatment in HDL-C

    Time frame: 24 weeks

  3. Percent change from baseline to 24 weeks of treatment in LDL-C

    Time frame: 24 weeks

07

Study locations

110 sites
  • Site 008
    Brno, Czech Republic
  • Site 009
    Brno, Czech Republic
  • Site 010
    Brno, Czech Republic
  • Site 015
    Hradisk, Czech Republic
  • Site 019
    Karlovy Vary, Czech Republic
  • Site 014
    Kladno, Czech Republic
  • Site 005
    Nymburk, Czech Republic
  • Site 012
    Olomouc, Czech Republic
  • Site 013
    Olomouc, Czech Republic
  • Site 007
    Plzen, Czech Republic
  • Site 018
    Plzeň, Czech Republic
  • Site 001
    Prague, Czech Republic
  • Site 002
    Prague, Czech Republic
  • Site 003
    Prague, Czech Republic
  • Site 004
    Prague, Czech Republic
  • Site 016
    Pribram, Czech Republic
  • Site 017
    Pribram, Czech Republic
  • Site 011
    Slany, Czech Republic
  • Site 006
    Tabor, Czech Republic
  • Site 201
    Copenhagen, Denmark
  • Site 205
    Copenhagen, Denmark
  • Site 203
    Hvidovre, Denmark
  • Site 302
    Bouliac, France
  • Site 314
    Briollay, France
  • Site 318
    Corsept, France
  • Site 301
    Dijon, France
  • Site 317
    La Montagne, France
  • Site 321
    Le mesnil en Valee, France
  • Site 316
    Loudon, France
  • Site 308
    Mont de Marsan, France
  • Site 312
    Murs-Erigne, France
  • Site 310
    Nantes, France
  • Site 304
    Niort, France
  • Site 319
    Orvault, France
  • Site 306
    Paris, France
  • Site 305
    Pouilly en Auxois, France
  • Site 307
    Rouen, France
  • Site 311
    Rouen, France
  • Site 303
    Saint Justin, France
  • Site 315
    Thouars, France
  • Site 309
    Vieux Conde, France
  • Site 313
    Vihiers, France
  • Site 320
    Vue, France
  • Site 109
    Deidesheim, Germany
  • Site 108
    Frankfurt, Germany
  • Site 101
    Freiburg, Germany
  • Site 111
    Hamburg, Germany
  • Site 103
    Hannover, Germany
  • Site 104
    Ilvesheim, Germany
  • Site 110
    Kassel, Germany
  • Site 106
    Mannheim, Germany
  • Site 114
    Munchen, Germany
  • Site 113
    Neu-Anspach, Germany
  • Site 105
    Offenbach, Germany
  • Site 107
    Offenbach, Germany
  • Site 115
    Paderborn Kernstadt, Germany
  • Site 102
    Rodgau, Germany
  • Site 112
    Wermsdorf, Germany
  • Site 406
    Bekescsaba, Hungary
  • Site 401
    Budapest, Hungary
  • Site 411
    Budapest, Hungary
  • Site 412
    Budapest, Hungary
  • Site 405
    Debrecen, Hungary
  • Site 402
    Gyongyos, Hungary
  • Site 409
    Gyula, Hungary
  • Site 410
    Kecskemet, Hungary
  • Site 404
    Miskolc, Hungary
  • Site 413
    Mosonmagyarovar, Hungary
  • Site 407
    Oroshaza, Hungary
  • Site 408
    Szeged, Hungary
  • Site 403
    Szolnok, Hungary
  • Site 508
    Breda, Netherlands
  • Site 509
    De Bilt, Netherlands
  • Site 511
    Den Bosch, Netherlands
  • Site 502
    Eindhoven, Netherlands
  • Site 514
    Eindhoven, Netherlands
  • Site 503
    Groningen, Netherlands
  • Site 512
    Hengelo, Netherlands
  • Site 506
    Leiden, Netherlands
  • Site 507
    Nijmegen, Netherlands
  • Site 501
    Rotterdam, Netherlands
  • Site 513
    Tiel, Netherlands
  • Site 510
    Utrecht, Netherlands
  • Site 505
    Velp, Netherlands
  • Site 504
    Zoetermeer, Netherlands
  • Site 606
    Chrzanow, Poland
  • Site 601
    Gdansk, Poland
  • Site 603
    Katowice, Poland
  • Site 609
    Sopot, Poland
  • Site 602
    Warsaw, Poland
  • Site 607
    Warsaw, Poland
  • Site 608
    Warsaw, Poland
  • Site 605
    Wroclaw, Poland
  • Site 610
    Wroclaw, Poland
  • Site 604
    Zabrze, Poland
  • Site 701
    Dnipropetrovsk, Ukraine
  • Site 702
    Dnipropetrovsk, Ukraine
  • Site 709
    Dnipropetrovsk, Ukraine
  • Site 712
    Donetsk, Ukraine
  • Site 703
    Kharkiv, Ukraine

Showing the first 100 of 110 sites across 8 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2006
First posted
Jul 7, 2006
Start
Nov 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Last update
Jul 8, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00349375
First posted
Jul 7, 2006
Start date
Nov 2005
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Jul 8, 2009

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fenofibrate · Simvastatin

Start the discussion